Short acting Insulin Market Size, Share, Trends, Growth Outlook

Short acting Insulin Market is estimated to increase at a Compounded Annual Growth Rate of 3.5% CAGR over the forecast period from 2024 to 2030

The Short acting Insulin Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Drug (Apidra (Glulisine), Novolog/Novorapid, Humalog (Lispro), Novolin (Actrapid), Insuman, Humulin, FIASP, Admelog).

An Introduction to Short acting Insulin Market in 2024

The market for short-acting insulin formulations remains integral to the management of diabetes mellitus in 2024, providing rapid-acting options for controlling postprandial glucose levels and managing hyperglycemic episodes. Short-acting insulins, such as regular human insulin and rapid-acting analogs like insulin lispro and insulin aspart, are administered shortly before meals to mimic the physiological insulin response to food intake. With advancements in insulin delivery devices, such as insulin pens and insulin pumps, short-acting insulin formulations offer convenient and precise dosing options for individuals with diabetes. Moreover, the market is influenced by innovations in insulin analog design, formulation technology, and adjunctive therapies, aiming to optimize glycemic control, minimize hypoglycemia risk, and improve patient adherence to insulin regimens. Additionally, ongoing research explores the potential of closed-loop insulin delivery systems and digital health solutions to further enhance the efficacy and safety of short-acting insulins, reflecting the continuous evolution of diabetes management strategies and the pursuit of personalized and patient-centered care approaches.

Market Trend: Increasing Demand for Personalized Diabetes Management

A significant trend in the short-acting insulin market is the increasing demand for personalized diabetes management. As the prevalence of diabetes continues to rise globally, there is a growing recognition of the need for tailored treatment approaches that address individual patient characteristics, lifestyle factors, and glucose variability. Short-acting insulin, such as regular insulin (R), plays a vital role in managing postprandial glucose levels and correcting hyperglycemia, particularly in patients with type 1 diabetes and some individuals with type 2 diabetes. With the advent of continuous glucose monitoring (CGM) systems, insulin pumps, and digital health technologies, healthcare providers are increasingly able to customize insulin therapy regimens based on real-time glucose data, carbohydrate intake, physical activity, and other patient-specific parameters. This trend towards personalized diabetes management drives market growth and innovation in short-acting insulin formulations, delivery devices, and integrated digital solutions that empower patients to achieve optimal glycemic control and improve their quality of life.

Market Driver: Advancements in Diabetes Care and Treatment Paradigms

A primary driver propelling the short-acting insulin market forward is the advancements in diabetes care and treatment paradigms. Over the past few decades, there have been significant advancements in the understanding of diabetes pathophysiology, insulin pharmacokinetics, and glucose monitoring technologies, leading to the development of more effective and convenient insulin therapies. Short-acting insulin analogs, such as insulin lispro and insulin aspart, offer faster onset of action, shorter duration of action, and greater flexibility in dosing compared to regular human insulin, making them preferred options for mealtime insulin coverage and correction of high blood sugar levels. Additionally, the integration of insulin pumps, closed-loop systems, and smart insulin delivery devices into diabetes management regimens enables precise insulin dosing, improved glycemic control, and reduced risk of hypoglycemia. This driver underscores the role of advancements in diabetes care and treatment paradigms in driving market demand for short-acting insulin products and shaping the future of diabetes management.

Market Opportunity: Expansion into Wearable Insulin Delivery Technologies

An opportunity within the short-acting insulin market lies in the expansion into wearable insulin delivery technologies. As patients seek more convenient and discreet options for insulin administration, there is growing interest in wearable insulin delivery devices that offer continuous subcutaneous insulin infusion (CSII) therapy. While traditional insulin pumps have been available for several decades, recent advancements in miniaturization, connectivity, and user interface design have led to the development of compact and user-friendly wearable insulin delivery systems. These devices, commonly known as patch pumps or wearable insulin patches, adhere to the skin and deliver insulin continuously or on-demand, eliminating the need for multiple daily injections and offering greater freedom and flexibility in insulin dosing. By expanding their product portfolios to include wearable insulin delivery technologies, manufacturers can capitalize on the growing demand for convenient and discreet insulin administration options, differentiate their offerings in the competitive landscape, and improve patient adherence and satisfaction. This opportunity for innovation and expansion enables companies to meet the evolving needs and preferences of patients with diabetes and drive market growth in the short-acting insulin segment.

Short-acting Insulin Market Share Analysis: FIASP

The fast-growing segment in the Short-acting Insulin Market is FIASP (Faster-acting Insulin Aspart). FIASP is a formulation of insulin aspart that has been engineered for faster absorption and action compared to traditional short-acting insulins. Its rapid onset of action makes it particularly suitable for controlling postprandial glucose levels in people with diabetes. FIASP offers the advantage of flexibility in dosing, allowing patients to administer it just before or immediately after meals, thereby better mimicking the physiological insulin response to food intake. Additionally, its faster action profile can help reduce post-meal hyperglycemia and improve glycemic control throughout the day. These benefits have contributed to the growing popularity of FIASP among healthcare providers and patients, driving its rapid growth in the short-acting insulin market.

Short acting Insulin Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossBiocon Ltd, Eli Lilly and Company, Novo Nordisk A/S, Pfizer Inc, Sanofi SA

Short acting Insulin Market Segmentation

By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Short acting Insulin Market Companies

Biocon Ltd
Eli Lilly and Company
Novo Nordisk A/S
Pfizer Inc
Sanofi SA

Reasons to Buy the Short acting Insulin Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Short acting Insulin Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Short acting Insulin Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Short acting Insulin Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Short acting Insulin Market Size Outlook, $ Million, 2021 to 2030
3.2 Short acting Insulin Market Outlook by Type, $ Million, 2021 to 2030
3.3 Short acting Insulin Market Outlook by Product, $ Million, 2021 to 2030
3.4 Short acting Insulin Market Outlook by Application, $ Million, 2021 to 2030
3.5 Short acting Insulin Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Short acting Insulin Industry
4.2 Key Market Trends in Short acting Insulin Industry
4.3 Potential Opportunities in Short acting Insulin Industry
4.4 Key Challenges in Short acting Insulin Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Short acting Insulin Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Short acting Insulin Market Outlook by Segments
7.1 Short acting Insulin Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog

8 North America Short acting Insulin Market Analysis and Outlook To 2030
8.1 Introduction to North America Short acting Insulin Markets in 2024
8.2 North America Short acting Insulin Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Short acting Insulin Market size Outlook by Segments, 2021-2030
By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog

9 Europe Short acting Insulin Market Analysis and Outlook To 2030
9.1 Introduction to Europe Short acting Insulin Markets in 2024
9.2 Europe Short acting Insulin Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Short acting Insulin Market Size Outlook by Segments, 2021-2030
By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog

10 Asia Pacific Short acting Insulin Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Short acting Insulin Markets in 2024
10.2 Asia Pacific Short acting Insulin Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Short acting Insulin Market size Outlook by Segments, 2021-2030
By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog

11 South America Short acting Insulin Market Analysis and Outlook To 2030
11.1 Introduction to South America Short acting Insulin Markets in 2024
11.2 South America Short acting Insulin Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Short acting Insulin Market size Outlook by Segments, 2021-2030
By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog
12 Middle East and Africa Short acting Insulin Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Short acting Insulin Markets in 2024
12.2 Middle East and Africa Short acting Insulin Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Short acting Insulin Market size Outlook by Segments, 2021-2030
By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Biocon Ltd
Eli Lilly and Company
Novo Nordisk A/S
Pfizer Inc
Sanofi SA

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug
Short-acting Insulins
-Apidra (Glulisine)
-Novolog/Novorapid
-Humalog (Lispro)
-Novolin (Actrapid)
-Insuman
-Humulin
-FIASP
-Admelog
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)